Innovation journal posts cancer therapy
- The Innovation Medicine published a February 4 commentary detailing early KRAS G12D drug results, centering on TSN1611 and zoldonrasib in solid tumors. - TSN1611 produced tumor shrinkage at 200-400 milligram doses across cancers, while zoldonrasib posted a 61% response rate in 18 lung-cancer patients. - KRAS G12D is the most common KRAS mutation, especially in pancreatic cancer. (the-innovation.org)
Cancer cells often run on broken growth switches. One of the hardest to drug has been KRAS G12D, a mutation common in pancreatic, colorectal, and lung tumors. (the-innovation.org) A February 4 commentary in *The Innovation Medicine* says that is starting to change, with early human data now emerging for several KRAS G12D-targeted drugs. The paper is titled “Breaking undruggable: The emergence of KRASG12D targeted therapy.” (the-innovation.org) KRAS is a protein that acts like an on-off switch for cell growth. The G12D mutation jams that switch in the “on” position, pushing tumor cells to keep dividing. (the-innovation.org) Researchers long called KRAS “undruggable” because the protein surface is smooth and offers few places for a medicine to grab onto. Drugs for the KRAS G12C subtype reached the market first, including Lumakras and Krazati. (the-innovation.org) The new commentary highlights TSN1611, a first-in-human drug from a phase 1/2 trial registered as NCT06385925 for advanced solid tumors with KRAS G12D mutations. The study is open-label, multicenter, and includes dose escalation and dose expansion. (clinicaltrials.gov) (mdanderson.org) According to the commentary, TSN1611 produced tumor shrinkage across multiple cancer types at doses of 200 to 400 milligrams. An American Society of Clinical Oncology abstract also said the drug was well tolerated and showed preliminary tumor shrinkage in refractory KRAS G12D-mutant tumors. (the-innovation.org) (ascopubs.org) The same commentary points to zoldonrasib, another KRAS G12D inhibitor, in previously treated non-small cell lung cancer. In an evaluable group of 18 patients, it reported a 61.0% objective response rate and an 89.0% disease control rate. (the-innovation.org) It also cites HRS-4642, a non-covalent KRAS G12D inhibitor from Hengrui Medicine. The paper says two heavily pretreated lung-cancer patients had target-lesion reductions of 53.0% and 31.0%. (the-innovation.org) The reason researchers care is the scale of the target. The commentary says KRAS G12D accounts for 29% of KRAS mutations overall and appears in 39.5% of pancreatic ductal adenocarcinomas, 15.0% of colorectal cancers, and 4.9% of non-small cell lung cancers. (the-innovation.org) The TSN1611 trial is still recruiting, and its phase 2 portion is designed to test efficacy more formally in pancreatic cancer, colorectal cancer, non-small cell lung cancer, and other solid tumors. Early shrinkage signals are not the same as proof that patients live longer or stay progression-free longer. (clinicaltrials.gov) (cdek.pharmacy.purdue.edu) For now, the paper’s message is narrow but concrete: KRAS G12D is no longer being discussed only as a lab target. It is now producing measurable responses in early-stage human studies, with larger trials still ahead. (the-innovation.org)
